CA2786762C - Anaesthetic formulation - Google Patents
Anaesthetic formulation Download PDFInfo
- Publication number
- CA2786762C CA2786762C CA2786762A CA2786762A CA2786762C CA 2786762 C CA2786762 C CA 2786762C CA 2786762 A CA2786762 A CA 2786762A CA 2786762 A CA2786762 A CA 2786762A CA 2786762 C CA2786762 C CA 2786762C
- Authority
- CA
- Canada
- Prior art keywords
- cyclodextrin
- alphaxalone
- anaesthetic
- formulation
- neuroactive steroid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Anesthesiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29724910P | 2010-01-21 | 2010-01-21 | |
| US61/297,249 | 2010-01-21 | ||
| US38531810P | 2010-09-22 | 2010-09-22 | |
| US61/385,318 | 2010-09-22 | ||
| PCT/AU2011/000050 WO2011088503A1 (en) | 2010-01-21 | 2011-01-19 | Anaesthetic formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2786762A1 CA2786762A1 (en) | 2011-07-28 |
| CA2786762C true CA2786762C (en) | 2017-12-05 |
Family
ID=44306295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2786762A Active CA2786762C (en) | 2010-01-21 | 2011-01-19 | Anaesthetic formulation |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8697678B2 (enExample) |
| EP (1) | EP2525798B1 (enExample) |
| JP (1) | JP5930311B2 (enExample) |
| KR (1) | KR101747476B1 (enExample) |
| CN (1) | CN102802635B (enExample) |
| AU (1) | AU2011207103B2 (enExample) |
| BR (1) | BR112012017800B1 (enExample) |
| CA (1) | CA2786762C (enExample) |
| CL (1) | CL2012002032A1 (enExample) |
| CY (1) | CY1119947T1 (enExample) |
| DK (1) | DK2525798T3 (enExample) |
| ES (1) | ES2646829T3 (enExample) |
| GB (2) | GB2484244B (enExample) |
| HR (1) | HRP20171699T1 (enExample) |
| HU (1) | HUE035441T2 (enExample) |
| LT (1) | LT2525798T (enExample) |
| NO (1) | NO2525798T3 (enExample) |
| NZ (1) | NZ601255A (enExample) |
| PL (1) | PL2525798T3 (enExample) |
| PT (1) | PT2525798T (enExample) |
| RS (1) | RS56576B1 (enExample) |
| RU (1) | RU2574022C2 (enExample) |
| SG (1) | SG181997A1 (enExample) |
| SI (1) | SI2525798T1 (enExample) |
| SM (1) | SMT201700518T1 (enExample) |
| WO (1) | WO2011088503A1 (enExample) |
| ZA (1) | ZA201205370B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101583620B (zh) | 2005-11-28 | 2016-08-17 | 马里纳斯医药公司 | 加奈索酮组合物及其制备和使用方法 |
| WO2013043985A1 (en) | 2011-09-23 | 2013-03-28 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| HRP20200567T1 (hr) * | 2011-11-29 | 2020-06-26 | Jurox Pty Ltd | Stabilni injektabilni farmaceutski pripravci koji sadrže 2-hidroksipropil-beta-ciklodekstrin i alfaksalon |
| WO2013112605A2 (en) * | 2012-01-23 | 2013-08-01 | Sage Therapeutics, Inc. | Neuroactive steroid formulations and methods of treating cns disorders |
| US20140050789A1 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| IL275725B (en) * | 2012-08-21 | 2022-08-01 | Sage Therapeutics Inc | Treatment methods for epilepsy and status epilepticus |
| ES3056529T3 (en) | 2012-11-09 | 2026-02-23 | Drawbridge Pharmaceuticals Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
| EP4335505A3 (en) * | 2012-11-30 | 2024-06-05 | The Regents of The University of California | Anticonvulsant activity of steroids |
| WO2015134670A1 (en) * | 2014-03-05 | 2015-09-11 | Mingbao Zhang | Deuterated ganaxolone derivatives |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| IL252848B2 (en) * | 2015-02-06 | 2024-07-01 | Marinus Pharmaceuticals Inc | Intravenous Genaxolone Formulations and Their Use in the Treatment of Epileptic Seizures and Other Seizure Disorders |
| AR105044A1 (es) * | 2015-06-18 | 2017-08-30 | Sage Therapeutics Inc | Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente |
| US9585867B2 (en) | 2015-08-06 | 2017-03-07 | Charles Everett Ankner | Cannabinod formulation for the sedation of a human or animal |
| EP3362042A1 (en) | 2015-10-16 | 2018-08-22 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| SG11201807785VA (en) | 2016-03-08 | 2018-10-30 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
| WO2018031748A1 (en) | 2016-08-11 | 2018-02-15 | Ovid Therapeutics Inc. | Methods and compositions for treatment of epileptic disorders |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| JP6986140B2 (ja) | 2018-04-16 | 2021-12-22 | 川崎重工業株式会社 | ベルトコンベヤ |
| AU2019297195B2 (en) * | 2018-07-03 | 2025-01-30 | Drawbridge Pharmaceuticals Pty Ltd | Neuroactive steroids and methods of preparation |
| WO2020118142A1 (en) | 2018-12-07 | 2020-06-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of pospartum depression |
| AU2019396217A1 (en) * | 2018-12-10 | 2021-07-08 | Halo Science LLC | Stable formulations of anesthetics and associated dosage forms |
| CA3145923A1 (en) | 2019-08-05 | 2021-02-11 | David Czekai | Ganaxolone for use in treatment of status epilepticus |
| WO2021113834A1 (en) | 2019-12-06 | 2021-06-10 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating tuberous sclerosis complex |
| US11969434B1 (en) | 2022-08-29 | 2024-04-30 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
| US12186327B2 (en) | 2022-08-29 | 2025-01-07 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69006259T2 (de) * | 1989-05-24 | 1994-06-09 | Innovet Inc | Hypoallergene anästhesierende/hypnotische steroide Arzneizubereitung. |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| WO1993017711A1 (en) * | 1992-03-11 | 1993-09-16 | Australian Commercial Research & Development Limited | New cyclodextrins and new formulated drugs |
| US5472954A (en) * | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
| JP4227675B2 (ja) * | 1996-10-25 | 2009-02-18 | 康武 日地 | 神経毒軽減麻酔剤 |
| AUPQ633900A0 (en) | 2000-03-20 | 2000-04-15 | Jurox Pty Ltd | Anaesthetic composition |
| RU2288921C2 (ru) * | 2000-12-19 | 2006-12-10 | Калифорниа Инститьют оф Текнолоджи | Композиции, содержащие комплексы включения |
| US7034013B2 (en) * | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| CA2441744C (en) * | 2001-03-20 | 2011-07-12 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| IL152575A (en) * | 2002-10-31 | 2008-12-29 | Transpharma Medical Ltd | A skin-to-skin transmission system of water-insoluble drugs |
| CN101583620B (zh) * | 2005-11-28 | 2016-08-17 | 马里纳斯医药公司 | 加奈索酮组合物及其制备和使用方法 |
-
2011
- 2011-01-19 CA CA2786762A patent/CA2786762C/en active Active
- 2011-01-19 CN CN201180013975.2A patent/CN102802635B/zh not_active Expired - Fee Related
- 2011-01-19 HU HUE11734245A patent/HUE035441T2/en unknown
- 2011-01-19 LT LTEP11734245.1T patent/LT2525798T/lt unknown
- 2011-01-19 PL PL11734245T patent/PL2525798T3/pl unknown
- 2011-01-19 SM SM20170518T patent/SMT201700518T1/it unknown
- 2011-01-19 AU AU2011207103A patent/AU2011207103B2/en active Active
- 2011-01-19 NZ NZ601255A patent/NZ601255A/xx not_active IP Right Cessation
- 2011-01-19 US US13/574,201 patent/US8697678B2/en active Active
- 2011-01-19 GB GB1201842.0A patent/GB2484244B/en active Active
- 2011-01-19 SI SI201131342T patent/SI2525798T1/en unknown
- 2011-01-19 ES ES11734245.1T patent/ES2646829T3/es active Active
- 2011-01-19 RS RS20171135A patent/RS56576B1/sr unknown
- 2011-01-19 SG SG2012050159A patent/SG181997A1/en unknown
- 2011-01-19 WO PCT/AU2011/000050 patent/WO2011088503A1/en not_active Ceased
- 2011-01-19 JP JP2012549208A patent/JP5930311B2/ja active Active
- 2011-01-19 GB GB1210657.1A patent/GB2491491B/en active Active
- 2011-01-19 NO NO11734245A patent/NO2525798T3/no unknown
- 2011-01-19 DK DK11734245.1T patent/DK2525798T3/da active
- 2011-01-19 BR BR112012017800-8A patent/BR112012017800B1/pt not_active IP Right Cessation
- 2011-01-19 RU RU2012134321/15A patent/RU2574022C2/ru active
- 2011-01-19 PT PT117342451T patent/PT2525798T/pt unknown
- 2011-01-19 KR KR1020127021761A patent/KR101747476B1/ko active Active
- 2011-01-19 HR HRP20171699TT patent/HRP20171699T1/hr unknown
- 2011-01-19 EP EP11734245.1A patent/EP2525798B1/en active Active
-
2012
- 2012-07-18 ZA ZA2012/05370A patent/ZA201205370B/en unknown
- 2012-07-20 CL CL2012002032A patent/CL2012002032A1/es unknown
-
2013
- 2013-11-01 US US14/069,751 patent/US8975245B2/en active Active
-
2017
- 2017-11-07 CY CY20171101164T patent/CY1119947T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2786762C (en) | Anaesthetic formulation | |
| PL199652B1 (pl) | Sposób wytwarzania stałych kompozycji farmaceutycznych | |
| US20240374568A1 (en) | Parenteral liquid preparation comprising carbamate compound | |
| KR20130113428A (ko) | 음이온-양이온성 환형다당류 조성물인 벤다무스틴 | |
| AU2013200895B2 (en) | Anaesthetic formulation | |
| AU2014200491A1 (en) | Anaesthetic formulation | |
| JP2005520856A (ja) | 貯蔵時に安定なエプレレノン製剤 | |
| Singh et al. | Pharmaceutical applications of cyclodextrins | |
| Sear | New and Upcoming Drugs: Intravenous Anesthetic Agents | |
| ABOUIL-ENEIN | Pharmaceutical Applications of Cyclodextrins | |
| BR112019011914B1 (pt) | Formulação líquida parenteral, composição injetável, e, método para preparar uma formulação líquida parenteral | |
| CZ20001636A3 (cs) | Farmaceutické přípravky obsahující cyklodextriny a taxoidy | |
| HK1125047A (en) | Aqueous anaesthetic compositions comprising propofol | |
| EP1511517A1 (de) | Formulierung zur parenteralen applikation eines na-kanal-blockers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20151029 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD Year of fee payment: 14 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250108 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250109 |